RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 05 2025
0mins
Source: Newsfilter
New Laboratory Lease Agreement: RetinalGenix Technologies has signed a lease with MBC BioLabs for a new lab in San Carlos, California, aimed at advancing their DNA/RNA/GPS Pharmaco-Genetic Mapping platform and exploring drug repurposing for conditions like dementia and macular degeneration.
Strategic Collaborations and Research Focus: The company is looking to expand clinical studies and collaborate with experts in the field, while also leveraging advanced genetic profiling to enhance therapeutic strategies for neurodegenerative diseases.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
